CAPTRUST Financial Advisors
HRTX icon

CAPTRUST Financial Advisors’s Heron Therapeutics HRTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22K Buy
51,547
+4,266
+9% +$3.42K ﹤0.01% 3198
2026
Q1 		$37.8K Buy
47,281
+5,691
+14% +$6.59K ﹤0.01% 2923
2025
Q4 		$54.1K Sell
41,590
-7,366
-15% -$9.1K ﹤0.01% 2675
2025
Q3 		$61.7K Buy
48,956
+1,335
+3% +$2.12K ﹤0.01% 2547
2025
Q2 		$98.6K Buy
+47,621
New +$97.2K ﹤0.01% 2374
2024
Q1 		– Sell
-51,102
Closed -$86.9K – 2381
2023
Q4 		$86.9K Buy
51,102
+33,390
+189% +$36.8K ﹤0.01% 2542
2023
Q3 		$18.2K Sell
17,712
-6,198
-26% -$8.82K ﹤0.01% 2524
2023
Q2 		$27.7K Sell
23,910
-1,642
-6% -$2.93K ﹤0.01% 2452
2023
Q1 		$38.6K Buy
+25,552
New +$64K ﹤0.01% 2226
2022
Q4 		– Sell
-21,198
Closed -$89K – 2118
2022
Q3 		$89K Buy
21,198
+20,631
+3,639% +$80.7K ﹤0.01% 1947
2022
Q2 		$2K Sell
567
-518
-48% -$2.08K ﹤0.01% 4466
2022
Q1 		$6K Buy
1,085
+564
+108% +$4.13K ﹤0.01% 4065
2021
Q4 		$5K Sell
521
-370
-42% -$3.78K ﹤0.01% 4068
2021
Q3 		$10K Sell
891
-103
-10% -$1.25K ﹤0.01% 3605
2021
Q2 		$15K Buy
994
+504
+103% +$8.02K ﹤0.01% 3305
2021
Q1 		$8K Buy
490
+390
+390% +$6.95K ﹤0.01% 3540
2020
Q4 		$2K Hold
100
– – ﹤0.01% 3117
2020
Q3 		$2K Sell
100
-100
-50% -$1.56K ﹤0.01% 2766
2020
Q2 		$3K Buy
+200
New +$3.29K ﹤0.01% 2511
2019
Q4 		– Sell
-1,396
Closed -$26K – 1358
2019
Q3 		$26K Buy
1,396
+1,196
+598% +$22K ﹤0.01% 1223
2019
Q2 		$4K Hold
200
– – ﹤0.01% 1694
2019
Q1 		$5K Hold
200
– – ﹤0.01% 1526
2018
Q4 		$5K Hold
200
– – ﹤0.01% 1327
2018
Q3 		$6K Buy
+200
New +$7.45K ﹤0.01% 1330

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

CAPTRUST Financial Advisors's HRTX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Heron Therapeutics (HRTX) stake by 9% in Q2 2026, buying an estimated $3.42K and bringing the position to 51,547 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #3198.

CAPTRUST Financial Advisors first reported a position in HRTX in Q3 2018 and has held it in 24 quarters since. The position peaked at $98.6K in Q2 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • CAPTRUST Financial Advisors held 51,547 shares of Heron Therapeutics worth $22K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 4,266 Heron Therapeutics shares in Q2 2026, an estimated $3.42K.
  • Heron Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3198 holding.
  • CAPTRUST Financial Advisors first reported a position in Heron Therapeutics in Q3 2018 and has held it in 24 quarters since.
  • CAPTRUST Financial Advisors's Heron Therapeutics position peaked at $98.6K in Q2 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.